8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Nov 5, 2025·SEC
Material company update
Oct 27, 2025·SEC
X4 Pharmaceuticals, Inc.(XFOR)Earnings, Financials & Key Ratios
XFOR•NASDAQ
$4.23
Price updated Jun 30, 2026
AboutX4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.Show more
- Revenue$35M+1273.2%
- EBITDA-$86M-140.4%
- Net Income-$79M-111.5%
- EPS (Diluted)-1.87+66.5%
- Gross Margin82.18%+19.4%
- EBITDA Margin-243.8%+82.5%
- Operating Margin-247.44%+82.6%
- Net Margin-225.55%+84.6%
- ROE-75.99%+25.7%
XFOR Price & Volume
X4 Pharmaceuticals, Inc. (XFOR) stock price & volume — 10-year historical chart
Loading chart...
Orphan Drug Commercialization Faces Diagnostic Adoption Hurdles
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Commercialization and diagnostic adoption
Key Thesis Takeaways
- X4 Pharmaceuticals is navigating a high-stakes transition from a research-focused entity to a commercial-stage organization, supported by the recent FDA approval of XOLREMDI for WHIM syndrome.
- While the monetization of a Priority Review Voucher has provided a critical $216.9 million cash buffer as of 2026Q1, the company's long-term viability remains contingent on overcoming slow patient identification rates in the chronic neutropenia market.
- Investors should monitor the firm's ability to scale commercial infrastructure against its persistent operating losses, which reached -$20.3 million in 2026Q1, to determine if the current orphan drug pricing power can eventually offset high R&D intensity.
Verdict Logic
while the $216.9 million cash position provides near-term stability, the company's operating margin of -7.5% and the lack of consistent organic revenue growth warrant a cautious approach until patient adoption rates improve.
XFOR Growth Metrics
X4 Pharmaceuticals, Inc. (XFOR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years63.56%
3 Years-
TTM-71.26%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-783.12%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-313.15%
Return on Capital
10 Years-66.74%
5 Years-60.89%
3 Years-53.33%
Last Year-45.94%
XFOR Recent Earnings
X4 Pharmaceuticals, Inc. (XFOR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 4/12 qtrs (50%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.16+20.0%
$0.20
Rev
$2M-22.8%
$3M
Q2 2026
Mar 17, 2026Metric
Actual
Est
EPS
$0.22+38.9%
$0.36
Rev
$3M+48.2%
$2M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.69+12.7%
$0.79
Rev
$2M+1.8%
$2M
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$3.47+23.4%
$4.53
Rev
$2M-11.4%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.16vs $0.20+20.0% | $2Mvs $3M-22.8% |
| Q2 2026 | Mar 17, 2026 | $0.22vs $0.36+38.9% | $3Mvs $2M+48.2% |
| Q4 2025 | Nov 5, 2025 | $0.69vs $0.79+12.7% | $2Mvs $2M+1.8% |
| Q3 2025 | Aug 8, 2025 | $3.47vs $4.53+23.4% | $2Mvs $2M-11.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for X4 Pharmaceuticals, Inc. (XFOR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.23 | $534.2M | -2.26 | 1273.21% | -225.55% | -75.99% | — | |
| $3.36 | $14.53M | -3.08 | 3.7% | -264.73% | -62.1% | — | |
| $350.06 | $10.11B | -25.97 | -100% | — | -43.02% | — | |
| $109.32 | $8.93B | -29.63 | -16.72% | -612.17% | -25.02% | — | |
| $38.51 | $7.91B | -13.90 | — | — | -68.16% | — | |
| $5.23 | $1.28B | -20.12 | 22.09% | -13.58% | -38.11% | — |
Compare XFOR vs Peers
X4 Pharmaceuticals, Inc. (XFOR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XFOR SEC Filings & Documents
X4 Pharmaceuticals, Inc. (XFOR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when XFOR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XFOR Frequently Asked Questions
X4 Pharmaceuticals, Inc. (XFOR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is X4 Pharmaceuticals, Inc.'s revenue?
X4 Pharmaceuticals, Inc. (XFOR) reported $9.0M in revenue for fiscal year 2025.
How fast is X4 Pharmaceuticals, Inc. growing?
X4 Pharmaceuticals, Inc. (XFOR) grew revenue by 1273.2% over the past year. This is strong growth.
Is XFOR profitable?
X4 Pharmaceuticals, Inc. (XFOR) reported a net loss of $99.7M for fiscal year 2025.
Dividend & Returns
What is XFOR's return on equity?
X4 Pharmaceuticals, Inc. (XFOR) has a return on equity (ROE) of -76.0%. Negative ROE indicates the company is unprofitable.
What is X4 Pharmaceuticals, Inc.'s free cash flow?
X4 Pharmaceuticals, Inc. (XFOR) had negative free cash flow of $73.3M in fiscal year 2025, likely due to heavy capital investments.